BARNES-JEWISH HOSPITAL
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
About Us
News & Events
Maps & Locations
Contact Us
Google Search
PATIENT AND VISITOR INFORMATION
TREATMENT PROGRAMS
PREVENTION AND SCREENING
RESEARCH
HOW TO HELP
FOR HEALTH PROFESSIONALS
Go back to:
Home
Treatment Programs
Types of Cancer
Clinical Trial Search Results
Share
Soft-Tissue Sarcoma
NCI Information
Our Treatment Approach
Clinical Trials
Support Groups
Effects of Treatment
Treatment Team
NEW SEARCH
RETURN TO SEARCH RESULTS
Number:
201110130
Principal Investigator:
Van Tine, Brian
Title:
A randomized, multicenter, double-blind, phase II trial of KLH conjugated trivalent ganglioside vaccine containing GM2, GD2 Lactone and GD3 Lactone with immunological adjuvant OPT-821 vs. OPT-821 alone in metastatic sarcoma patients who are rendered disease free
Phase:
II
Disease Site:
Soft Tissue
Participating Site(s):
Main Campus
Map and Directions
Contact:
800-600-3606 or
info@ccadmin.wustl.edu
Description:
The purpose of this study is to compare the effects, good and/or bad, that the vaccine with OPT-821 or OPT-821 alone has on patients and their cancer.
More Information:
(Links will take you off this web site)
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)